Clinical and Experimental Vaccine Research最新文献_第4页

Immune modulation and possible pathological implications mediated by naturally produced immunoglobulin G idiotypes: from historical to recent experimental and clinical studies focused on atopic dermatitis. 由天然产生的免疫球蛋白 G 特异型介导的免疫调节和可能的病理影响：从历史到最近的实验和临床研究，重点是特应性皮炎。

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI: 10.7774/cevr.2024.13.1.1

Lucas Santander, Nicolle Rakanidis Machado, Beatriz Oliveira Fagundes, Jefferson Russo Victor

{"title":"Immune modulation and possible pathological implications mediated by naturally produced immunoglobulin G idiotypes: from historical to recent experimental and clinical studies focused on atopic dermatitis.","authors":"Lucas Santander, Nicolle Rakanidis Machado, Beatriz Oliveira Fagundes, Jefferson Russo Victor","doi":"10.7774/cevr.2024.13.1.1","DOIUrl":"10.7774/cevr.2024.13.1.1","url":null,"abstract":"Since the 1950s decade, it has been suggested that a naturally produced or induced repertoire of immunoglobulin G (IgG) idiotypes may exert some immunoregulatory functions. In the last decades, some more advanced theories have suggested that the repertoire of IgG idiotypes may influence the development or control of some atopic diseases. In atopic dermatitis (AD), some evidence indicated that the IgG repertoire obtained from these patients could effectively mediate regulatory functions on thymic and peripheral CD4+ and CD8+ T cells. Furthermore, some recent clinical trials have corroborated the hypothesis that IgG from AD patients can exert regulatory functions in vivo. Here, we revised some historical aspects that yield current approaches developed in vitro and in vivo to elucidate a recently proposed theory termed \"hooks without bait\" that can strengthen the broad spectrum of research about evaluating different sets of IgG idiotypes and determine their immunological effects.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"13 1","pages":"1-9"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute abdomen following COVID-19 vaccination: a systematic review. 接种 COVID-19 疫苗后的急性腹部：系统性综述。

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI: 10.7774/cevr.2024.13.1.42

Nelson Luis Cahuapaza-Gutierrez, Renzo Pajuelo-Vasquez, Cristina Quiroz-Narvaez, Flavia Rioja-Torres, María Quispe-Andahua, Fernando M Runzer-Colmenares

{"title":"Acute abdomen following COVID-19 vaccination: a systematic review.","authors":"Nelson Luis Cahuapaza-Gutierrez, Renzo Pajuelo-Vasquez, Cristina Quiroz-Narvaez, Flavia Rioja-Torres, María Quispe-Andahua, Fernando M Runzer-Colmenares","doi":"10.7774/cevr.2024.13.1.42","DOIUrl":"10.7774/cevr.2024.13.1.42","url":null,"abstract":"Purpose: Conduct a systematic review of case reports and case series regarding the development of acute abdomen following coronavirus disease 2019 (COVID-19) vaccination, to describe the possible association and the clinical and demographic characteristics in detail.Materials and methods: This study included case report studies and case series that focused on the development of acute abdomen following COVID-19 vaccination. Systematic review studies, literature, letters to the editor, brief comments, and so forth were excluded. PubMed, Scopus, EMBASE, and Web of Science databases were searched until June 15, 2023. The Joanna Briggs Institute tool was used to assess the risk of bias and the quality of the study. Descriptive data were presented as frequency, median, mean, and standard deviation.Results: Seventeen clinical case studies were identified, evaluating 17 patients with acute abdomen associated with COVID-19 vaccination, which included acute appendicitis (n=3), acute pancreatitis (n=9), diverticulitis (n=1), cholecystitis (n=2), and colitis (n=2). The COVID-19 vaccine most commonly linked to acute abdomen was Pfizer-BioNTech (messenger RNA), accounting for 64.71% of cases. Acute abdomen predominantly occurred after the first vaccine dose (52.94%). All patients responded objectively to medical (88.34%) and surgical (11.76%) treatment and were discharged within a few weeks. No cases of death were reported.Conclusion: Acute abdomen is a rare complication of great interest in the medical and surgical practice of COVID-19 vaccination. Our study is based on a small sample of patients; therefore, it is recommended to conduct future observational studies to fully elucidate the underlying mechanisms of this association.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"13 1","pages":"42-53"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute interstitial nephritis with acute kidney injury after COVID-19 vaccination: a case report. 接种 COVID-19 疫苗后出现急性肾损伤的急性间质性肾炎：病例报告。

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI: 10.7774/cevr.2024.13.1.68

Jimin Lim, Jin Hyuk Paek, Hyeong Chan Shin, Woo Yeong Park, Kyubok Jin, Misun Choe, Seungyeup Han, Yaerim Kim

{"title":"Acute interstitial nephritis with acute kidney injury after COVID-19 vaccination: a case report.","authors":"Jimin Lim, Jin Hyuk Paek, Hyeong Chan Shin, Woo Yeong Park, Kyubok Jin, Misun Choe, Seungyeup Han, Yaerim Kim","doi":"10.7774/cevr.2024.13.1.68","DOIUrl":"10.7774/cevr.2024.13.1.68","url":null,"abstract":"In the context of the massive spread of coronavirus disease 2019 (COVID-19), the development of a COVID-19 vaccine is urgently needed. The Pfizer-BioNTech COVID-19 vaccine has been widely applied across global populations. Herein, we report a case of acute interstitial nephritis with acute kidney injury in a young healthy subject after administration of the COVID-19 vaccine. A 20-year-old man was admitted with abdominal discomfort and nausea. He had received the Pfizer-BioNTech COVID-19 vaccine 6 days before. At 9 days after vaccination, his kidney function was decreased, with serum creatinine levels of 1.8 mg/dL. Even with supportive care with hydration, his kidney function worsened, and he underwent a kidney biopsy. The pathology findings revealed diffuse interstitial infiltration of inflammatory cells, predominantly comprising lymphocytes, with preservation of the glomerulus. No abnormal findings were noted by immunofluorescence or electron microscopy. Based on a diagnosis of drug-related acute interstitial nephritis, we treated the patient with high-dose prednisolone. After administration of prednisolone, kidney function slowly improved. A close linkage between COVID-19 vaccination and acute interstitial nephritis should be considered in the clinic, despite the low incidence.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"13 1","pages":"68-71"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current development of therapeutic vaccines for the treatment of chronic infectious diseases. 目前用于治疗慢性传染病的治疗性疫苗的开发情况。

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI: 10.7774/cevr.2024.13.1.21

Pil-Gu Park, Munazza Fatima, Timothy An, Ye-Eun Moon, Seungkyun Woo, Hyewon Youn, Kee-Jong Hong

{"title":"Current development of therapeutic vaccines for the treatment of chronic infectious diseases.","authors":"Pil-Gu Park, Munazza Fatima, Timothy An, Ye-Eun Moon, Seungkyun Woo, Hyewon Youn, Kee-Jong Hong","doi":"10.7774/cevr.2024.13.1.21","DOIUrl":"10.7774/cevr.2024.13.1.21","url":null,"abstract":"Chronic infectious diseases refer to diseases that require a long period of time from onset to cure or death, the use of therapeutic vaccines has recently emerged to eradicate diseases. Currently, clinical research is underway to develop therapeutic vaccines for chronic infectious diseases based on various vaccine formulations, and the recent success of the messenger RNA vaccine platform and efforts to apply it to therapeutic vaccines are having a positive impact on conquering chronic infectious diseases. However, since research on the development of therapeutic vaccines is still relatively lacking compared to prophylactic vaccines, there is a need to focus more on the development of therapeutic vaccines to overcome threats to human health caused by chronic infectious diseases. In order to accelerate the development of therapeutic vaccines for chronic infectious diseases in the future, it is necessary to establish a clear concept of therapeutic vaccines suitable for the characteristics of each chronic infectious disease, as well as standardize vaccine effectiveness evaluation methods, secure standards/reference materials, and simplify the vaccine approval procedure.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"13 1","pages":"21-27"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monitoring and evaluation of provincial classical swine fever immunization implementation with an E2 subunit vaccine in Jeju Island, South Korea. 监测和评估韩国济州岛使用 E2 亚单位疫苗进行省级传统猪瘟免疫接种的情况。

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI: 10.7774/cevr.2024.13.1.54

Guehwan Jang, Eun-Joo Kim, Seong-Cheol Cho, Sung-Up Moon, Myeong Hwa Lee, Jin A Ko, Seung Bo Ko, Jonghoo Lee, Changhee Lee

{"title":"Monitoring and evaluation of provincial classical swine fever immunization implementation with an E2 subunit vaccine in Jeju Island, South Korea.","authors":"Guehwan Jang, Eun-Joo Kim, Seong-Cheol Cho, Sung-Up Moon, Myeong Hwa Lee, Jin A Ko, Seung Bo Ko, Jonghoo Lee, Changhee Lee","doi":"10.7774/cevr.2024.13.1.54","DOIUrl":"10.7774/cevr.2024.13.1.54","url":null,"abstract":"Purpose: Accidental vaccination with a live attenuated low-virulence strain of Miyagi (LOM) vaccine led to the reemergence of classical swine fever virus (CSFV) in Jeju province, South Korea in 2014. To control the continual outbreaks of LOM-derived CSFV, the provincial government launched a provincial mass vaccination project using a CSF-E2 subunit vaccine. We conducted this study to assess the herd immunity level and outcomes of E2 vaccine-based immunization in breeding and growing herds on Jeju Island during 2020-2021.Materials and methods: A large-scale vaccination trial using the Bayovac CSF-E2 vaccine investigated its efficacy in breeding and growing herds under farm application conditions (10 CSFV-affected and three CSFV-naïve swine farms).Results: The level of herd immunity in each farm was classified into three (S1-S3) and six (G1-G6) profiles in breeding and growing herds, respectively. Immunity monitoring revealed a remarkable improvement in the herd immunity status in all farms. The majority (10/13) of farms, including CSFV-free farms, showed the S1G1 immunity profile in 2021, indicating the appropriate implementation of the advised vaccination regime. Moreover, there were significant decreases in Erns seropositivity from 100% to 50% and 25.9% to 4.3% at farm and pig levels, respectively. In particular, all farms were confirmed as CSFV free in the growing-finishing herds.Conclusion: Our large-scale trial demonstrated the effectiveness of the E2 subunit vaccine in establishing herd immunity stabilization and eliminating CSFV circulation in the affected farms and highlighted the need for a provincial vaccination policy to regain the CSF-free status on Jeju Island.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"13 1","pages":"54-62"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864886/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of BBV152 vaccine and ChAdOx1-S vaccine in preventing severe disease among vaccinated patients admitted to a designated COVID-19 hospital in India. BBV152 疫苗和 ChAdOx1-S 疫苗在印度 COVID-19 指定医院的接种患者中预防严重疾病的效果。

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI: 10.7774/cevr.2024.13.1.28

Rajaraman Nivetha, Ramesh Anshul, Subbarayan Sarojini, Chinnaian Sivagurunathan, Chandrasekar Janaganbose Maikandaan

{"title":"Effectiveness of BBV152 vaccine and ChAdOx1-S vaccine in preventing severe disease among vaccinated patients admitted to a designated COVID-19 hospital in India.","authors":"Rajaraman Nivetha, Ramesh Anshul, Subbarayan Sarojini, Chinnaian Sivagurunathan, Chandrasekar Janaganbose Maikandaan","doi":"10.7774/cevr.2024.13.1.28","DOIUrl":"10.7774/cevr.2024.13.1.28","url":null,"abstract":"Purpose: Coronavirus disease 2019 (COVID-19) is a highly formidable disease. Globally, multiple vaccines have been developed to prevent and manage this disease. However, the periodic mutations of severe acute respiratory syndrome coronavirus 2 variants cast doubt on the effectiveness of commonly used vaccines in mitigating severe disease in the Indian population. This study aimed to assess the effectiveness of the BBV152 vaccine and ChAdOx1-S vaccine in preventing severe forms of the disease.Materials and methods: This retrospective study, based on hospital records, was conducted on 204 vaccinated COVID-19 patients using a consecutive sampling approach. Data on their vaccination status, comorbidities, and high-resolution computed tomography lung reports' computed tomography severity scores were extracted from their medical records. Fisher's exact test and binomial logistic regression analysis were employed to assess the independent associations of various factors with the dependent variables.Results: Of the 204 records, 57.9% represented males, with a mean age of 61.5±9.8 years. Both vaccines demonstrated effective protection against severe illness (90.2%), with BBV152 offering slightly better protection compared to ChAdOx1-S. Male gender, partial vaccination, comorbid conditions, and the type of vaccine were identified as independent predictors of severe lung involvement.Conclusion: This study indicates that both vaccines were highly effective (90%) in preventing severe forms of the disease in fully vaccinated individuals. When comparing the two vaccines, BBV152 was slightly more effective than ChAdOx1-S in preventing severe COVID-19.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"13 1","pages":"28-34"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Humanized mouse model for vaccine evaluation: an overview. 用于疫苗评估的人源化小鼠模型：概述。

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI: 10.7774/cevr.2024.13.1.10

Shivani Kaushik, Lata Kumari, Rakesh Kumar Deepak

{"title":"Humanized mouse model for vaccine evaluation: an overview.","authors":"Shivani Kaushik, Lata Kumari, Rakesh Kumar Deepak","doi":"10.7774/cevr.2024.13.1.10","DOIUrl":"10.7774/cevr.2024.13.1.10","url":null,"abstract":"Animal models are essential in medical research for testing drugs and vaccines. These models differ from humans in various respects, so their results are not directly translatable in humans. To address this issue, humanized mice engrafted with functional human cells or tissue can be helpful. We propose using humanized mice that support the engraftment of human hematopoietic stem cells (HSCs) without irradiation to evaluate vaccines that influence patient immunity. For infectious diseases, several types of antigens and adjuvants have been developed and evaluated for vaccination. Peptide vaccines are generally used for their capability to fight cancer and infectious diseases. Evaluation of adjuvants is necessary as they induce inflammation, which is effective for an enhanced immune response but causes adverse effects in some individuals. A trial can be done on humanized mice to check the immunogenicity of a particular adjuvant and peptide combination. Messenger RNA has also emerged as a potential vaccine against viruses. These vaccines need to be tested with human immune cells because they work by producing a particular peptide of the pathogen. Humanized mice with human HSCs that can produce both myeloid and lymphoid cells show a similar immune response that these vaccines will produce in a patient.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"13 1","pages":"10-20"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador. 在萨尔瓦多使用的不同 COVID-19 强化接种方案的安全性和免疫原性。

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI: 10.7774/cevr.2024.13.1.35

Xochitl Sandoval, Rhina Domínguez, Delmy Recinos, Susana Zelaya, Patricia Cativo, Guillermo Horacio Docena

{"title":"Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador.","authors":"Xochitl Sandoval, Rhina Domínguez, Delmy Recinos, Susana Zelaya, Patricia Cativo, Guillermo Horacio Docena","doi":"10.7774/cevr.2024.13.1.35","DOIUrl":"10.7774/cevr.2024.13.1.35","url":null,"abstract":"Purpose: The effectiveness of coronavirus disease 2019 (COVID-19) vaccination schemes and the combination of vaccines of various platforms for administering booster doses is still being studied since it will depend on the population's response to vaccines. We aimed to evaluate the safety, protection, and immunogenicity of the Salvadorean population's third dose booster COVID-19 vaccine and the potential benefit of homologous vs. heterologous regimens.Materials and methods: This is an analytical observational cohort study in a population aged 18 to 65 years that was primarily vaccinated with AstraZeneca, Sinovac, or Pfizer/BioNTech. Volunteers were recruited (n=223) and followed up for 3 months after receiving the 3rd vaccine (BNT162b2) as a booster. Adverse reactions were monitored, serum anti-spike immunoglobulin G (IgG) was assessed by chemiluminescence, and a polymerase chain reaction was carried out when subjects developed clinical signs.Results: The cohorts finally included 199 participants, and we observed only mild adverse effects in all cohorts. A significant increase in specific IgG levels was found after the booster dose in all cohorts. The heterologous scheme with Sinovac showed the greatest increase in antibody titer, and a decrease was observed in all participants after 3 months. During the follow-up period, 30 participants showed symptomatology compatible with COVID-19, but only four were laboratory-confirmed and they showed mild clinical signs.Conclusion: These findings indicate that the booster doses used were safe and promoted an immediate increase in immunogenicity, which decreased over time. The heterologous regimen showed stronger immunogenicity compared to the messenger RNA-based homologous scheme.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"13 1","pages":"35-41"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Experimental animal models for development of human enterovirus vaccine 研制人肠病毒疫苗的实验动物模型

Clinical and Experimental Vaccine Research Pub Date : 2023-10-01 DOI: 10.7774/cevr.2023.12.4.291

Jae Min Song

{"title":"Experimental animal models for development of human enterovirus vaccine","authors":"Jae Min Song","doi":"10.7774/cevr.2023.12.4.291","DOIUrl":"https://doi.org/10.7774/cevr.2023.12.4.291","url":null,"abstract":"Enterovirus infections induce infectious diseases in young children, such as hand, foot, and mouth disease which is characterized by highly contagious rashes or blisters around the hands, feet, buttocks, and mouth. This predominantly arises from enterovirus A71 or coxsackievirus A16 infections and in severe cases, they can lead to encephalitis, paralysis, pulmonary edema, or even fatality, representing a global health threat. Due to the absence of effective therapeutic strategies for these infections, various experimental animal models are being investigated for the development of vaccines. During the early stages of research on enterovirus infections, non-human primate infections exhibited symptoms like those in humans, leading to their utilization as model animals. However, due to economic and ethical considerations, their current usage is limited. While enterovirus infections do not readily occur in mice, an infection model with mouse-adapted strain in neonatal mice has been employed. Cellular receptors have been identified in human cells, and genetically modified mice expressing these receptors have been used. Most recently, the utilization of Mongolian gerbil model is actively being considered and should be pursued for further animal model development. So, herein, we provide a summarized overview of the current portfolio of available enterovirus infection models, emphasizing their respective advantages and limitations.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"145 1","pages":"291 - 297"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135668168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaccines development in India: advances, regulation, and challenges. 印度的疫苗开发:进展、监管和挑战。

IF 2.7

Clinical and Experimental Vaccine Research Pub Date : 2023-07-01 DOI: 10.7774/cevr.2023.12.3.193

Rakshita Salalli, Jyoti Ram Dange, Sonia Dhiman, Teenu Sharma

{"title":"Vaccines development in India: advances, regulation, and challenges.","authors":"Rakshita Salalli, Jyoti Ram Dange, Sonia Dhiman, Teenu Sharma","doi":"10.7774/cevr.2023.12.3.193","DOIUrl":"https://doi.org/10.7774/cevr.2023.12.3.193","url":null,"abstract":"One of the most significant medical advancements in human history is the development of vaccines. Progress in vaccine development has always been greatly influenced by scientific human innovation. The main objective of vaccine development would be to acquire sufficient evidence of vaccine effectiveness, immunogenicity, safety, and/or quality to support requests for marketing approval. Vaccines are biological products that enhance the body's defenses against infectious diseases. From the first smallpox vaccine to the latest notable coronavirus disease 2019 nasal vaccine, India has come a long way. The development of numerous vaccines, driven by scientific innovation and advancement, combined with researcher's knowledge, has helped to reduce the global burden of disease and mortality rates. The Drugs and Cosmetics Rules of 1945 and the New Drugs and Clinical Trials Rules of 2019 specify the requirements and guidelines for CMC (chemistry, manufacturing, and controls) for all manufactured and imported vaccines, including those against coronavirus infections. This article provides an overview of the regulation pertaining to the development process, registration, and approval procedures for vaccines, particularly in India, along with their brief history.","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"12 3","pages":"193-208"},"PeriodicalIF":2.7,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b5/59/cevr-12-193.PMC10435768.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10105483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1